<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03820830</url>
  </required_header>
  <id_info>
    <org_study_id>IBCSG 59-19</org_study_id>
    <secondary_id>2018-003553-19</secondary_id>
    <secondary_id>BIG 18-02</secondary_id>
    <secondary_id>WI239003</secondary_id>
    <nct_id>NCT03820830</nct_id>
  </id_info>
  <brief_title>Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer</brief_title>
  <acronym>POLAR</acronym>
  <official_title>A Phase III Open-label, Multicenter, Randomized Trial of Adjuvant Palbociclib in Combination With Endocrine Therapy Versus Endocrine Therapy Alone for Patients With Hormone Receptor Positive / HER2-negative Resected Isolated Locoregional Recurrence of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      POLAR is a phase III clinical trial, which will test the safety and efficacy of an
      investigational combination of drugs to learn whether the combination of drugs works for a
      specific cancer. Palbociclib (Ibrance®) is the name of the investigational agent, which is
      assessed together with standard anti-hormone therapy in this study. Palbociclib is used to
      treat patients with hormone receptor-positive / HER2-negative breast cancer which has spread
      beyond the original tumor and/or to other organs.

      During this study, anti-hormone therapy will consist of either a selective estrogen receptor
      modulator (such as tamoxifen) or an aromatase inhibitor (anastrozole, letrozole, exemestane)
      or fulvestrant (Faslodex®). Premenopausal women and men may also receive a drug called an
      LHRH (luteinizing hormone-releasing hormone) agonist by injection.

      It is standard of care for people with hormone receptor positive breast cancer to take
      anti-hormone therapy. The study doctor will determine the type of standard anti-hormone
      therapy that will be given during this trial.

      The purpose of the POLAR study is to compare the effect of using 3 years of palbociclib in
      combination with standard anti-hormone therapy with standard anti-hormone therapy alone and
      to evaluate the time until the breast cancer returns, if it does return.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Local or regional recurrence of breast cancer after mastectomy or lumpectomy indicates a poor
      prognosis, and accompanies or precedes distant metastasis in a high proportion of patients.
      Patients with isolated locoregional recurrences (ILRR), without evidence of distant
      metastasis hold a substantial risk of developing subsequent distant metastasis, with 5-year
      survival probabilities ranging between 45% and 80% after locoregional recurrence. These
      outcomes show the powerful negative prognostic importance of ILRR events and the need for
      treatments beyond surgical removal of the ILRR.

      Adjuvant chemotherapy and endocrine therapies reduce the risk of relapse and death in
      patients with primary breast cancer. However, few data are available to inform the
      recommendation of systemic treatment for locoregional recurrence.

      The International Breast Cancer Studies Group carried out the CALOR trial, Chemotherapy as
      Adjuvant for Locally Recurrent breast cancer (IBCSG 27-02 / BIG 1-02 / NSABP B-37), in
      collaboration with the Breast International Group (BIG) and the National Surgical Adjuvant
      Breast and Bowel Project (NSABP), to establish whether chemotherapy improves the outcome of
      patients with ILRR. An updated, final analysis of CALOR after median follow-up of about 9
      years was published in the Journal of Clinical Oncology in April 2018, which confirmed
      chemotherapy benefitted patients with resected ER-negative ILRR and did not support the use
      of chemotherapy for ER-positive ILRR.

      CALOR results strongly suggest that tailoring treatment according to the disease
      characteristics of the recurrent lesion, in this case ILRR, provides a better indication of
      the possible responsiveness to treatment than relying on the characteristics of the primary
      tumor.

      Palbociclib has been granted FDA approval in the U.S. for the treatment of
      HR-positive/HER2-negative advanced breast cancer in combination with the hormonal treatments
      letrozole and fulvestrant given the unprecedented results in terms of efficacy of two pivotal
      clinical trials (PALOMA-2 and PALOMA-3). Palbociclib and other CDK4/6 inhibitors have also
      shown a good toxicity profile and therefore are ideal candidates for combination with
      hormonal therapy. CDK4/6 pathway activation is a well-known mechanism of resistance to
      endocrine therapy, indeed CDK4/6 inhibitors have shown activity in cellular models of
      acquired resistance to endocrine therapies.

      The reason for prolonged duration of palbociclib in the adjuvant setting (2 years) comes from
      the evidence of preclinical studies where cell senescence was investigated as an appealing
      mechanism of cell death and was indeed observed in vitro after exposure of breast cancer
      cells and tumors to a combination of endocrine therapy and palbociclib. It is therefore
      hypothesized that the longer patients receive combined treatment with palbociclib and an
      antiestrogen, the more likely they may derive prolonged clinical benefit.

      Based on the results of the CALOR trial and on strong evidence of activity of the combination
      of CDK4/6 inhibitors and endocrine therapy, the hypothesis of the POLAR trial is that the
      CDK4/6 inhibitor palbociclib in combination with endocrine therapy may be active as adjuvant
      therapy in patients with HR-positive/HER2-negative resected isolated locoregional recurrence
      of breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of invasive disease free survival of all randomized participants.</measure>
    <time_frame>Assessed from the date treatment starts until the date of first documented invasive local, regional or distant recurrence, a second invasive cancer or death, or until approximately 4 years after treatment stops.</time_frame>
    <description>Defined as the time from randomization until first appearance of invasive local, regional or distant recurrence (including invasive ipsilateral breast tumour recurrence), invasive contralateral breast cancer, a second (non-breast) invasive cancer, or death from any cause. The sites of first invasive disease events will be compared between treatment groups using a stratified log-rank test and will be tabulated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment related adverse events.</measure>
    <time_frame>Adverse events will be collected from the date consent is signed, and during treatment until 30-60 days after treatment stops.</time_frame>
    <description>Adverse events, defined as any untoward medical occurrence, will be collected using CTCAE v5. All grades for targeted adverse events will be collected and all grades ≥3 for non-targeted adverse events. The maximum grade of each targeted adverse event during the protocol treatment phase will be determined, the frequencies summarized and tabulated according to grade and treatment assignment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of breast cancer free interval of all randomized participants.</measure>
    <time_frame>Assessed from the date of randomization until the date of first documented breast cancer recurrence, or until approximately 4 years after treatment stops.</time_frame>
    <description>Defined as the time from randomization until the date of first documented appearance of invasive local, regional or distant recurrence (including ipsilateral tumour recurrence), or invasive contralateral breast cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of distant recurrence free interval of all randomized participants.</measure>
    <time_frame>Assessed from the date of randomization until the date of first documented distant disease progression, or until approximately 4 years after treatment stops.</time_frame>
    <description>Defined as the time from randomization until the date of first documented distant recurrence of breast cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall survival of all randomized participants.</measure>
    <time_frame>Assessed from the date of randomization until approximately 4 years after treatment stops, or until the date of death from any cause.</time_frame>
    <description>Defined as the time from randomization until death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Breast Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Palbociclib plus standard endocrine therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palbociclib 125 mg/day tablet taken orally for 21 days, followed by 7 days rest for 3 years from randomization, plus standard endocrine therapy for at least 3 years from randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard endocrine therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib 125mg</intervention_name>
    <description>Palbociclib 125 mg oral tablet taken daily for 3 years from randomization</description>
    <arm_group_label>Palbociclib plus standard endocrine therapy</arm_group_label>
    <other_name>Ibrance</other_name>
    <other_name>PD-0332991</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard endocrine therapy</intervention_name>
    <description>Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.</description>
    <arm_group_label>Palbociclib plus standard endocrine therapy</arm_group_label>
    <arm_group_label>Standard endocrine therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed invasive breast cancer, defined as first proven ipsilateral
             local and/or regional recurrence in the breast in at least one of these sites: breast;
             the chest wall including mastectomy scar and/or skin; axillary or internal mammary
             lymph nodes.

          -  Completion of locoregional therapy: gross excision of recurrence within 6 months prior
             to randomization; radiotherapy (if given) more than 2 weeks prior to randomization

          -  Negative or microscopically involved margins

          -  Female or male aged 18 years or older

          -  ECOG performance status 0 or 1

          -  Recurrent tumor must be hormone receptor positive: ER+ and/or PgR+ ≥1% by IHC

          -  Recurrent tumor must be HER2-negative (0, 1+, 2+ by IHC and/or ISH/FISH not
             amplified).Tumor with HER2 status 2+ by IHC must also be negative (not amplified) by
             ISH/FISH

          -  Normal hematological, renal, and liver function

          -  The patient agrees to make tumor (diagnostic core biopsy or surgical specimen of
             ipsilateral isolated locoregional recurrence) available for submission for central
             pathology review

          -  Patients must either be planned to initiate, or have already started, endocrine
             therapy for ipsilateral isolated locoregional recurrence

          -  Written Informed Consent prior to randomization

        Exclusion Criteria:

          -  Recurrence of any size with direct extension to the chest wall and/or to the skin
             (ulceration or skin nodules) not surgically removable

          -  Evidence of distant metastasis as based on conventional staging examinations
             (physical, chest X-ray or CT, abdominal ultrasound or CT, bone scintigraphy or
             FDG-PET-CT).

          -  Bilateral invasive breast cancer (in situ carcinoma of the contralateral breast is
             allowed)

          -  Inflammatory breast cancer

          -  Patients with a history of malignancy, other than invasive breast cancer, with the
             following exceptions: Patients diagnosed, treated and disease-free for at least 5
             years and deemed by the investigator to be at low risk for recurrence of that
             malignancy are eligible.

          -  Patients with the following malignancies are eligible, even if diagnosed and treated
             within the past 5 years: ductal carcinoma in situ of the breast; cervical cancer in
             situ; thyroid cancer in situ; non-metastatic, non-melanomatous skin cancers.

          -  Previous treatment with palbociclib or any other CDK 4/6 inhibitors

          -  Previous or planned chemotherapy or planned radiotherapy for the ipsilateral isolated
             locoregional recurrence (radiotherapy is allowed, but must be completed more than 2
             weeks prior to randomization)

          -  Concurrent disease or condition that would make the patient inappropriate for study
             participation or any serious medical disorder that would interfere with the patient's
             safety

          -  Contraindications or known hypersensitivity to the palbociclib or excipients

          -  Pregnant or lactating women; lactation has to stop before randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabetta Munzone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holly Shaw</last_name>
    <phone>+17168340900</phone>
    <email>ibcsg59_polar@fstrf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adriana Karausch</last_name>
    <email>ibcsg59_polar@fstrf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universität Graz (MUG)</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marija Balic, PD</last_name>
      <email>marija.balic@medunigraz.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck - Univ.-Klinik f. Frauenheilkunde</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Egle, PD</last_name>
      <email>daniel.egle@tirol-kliniken.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Salzburg</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Greil, Prof.</last_name>
      <email>r.greil@salk.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MUW - Universitätsklinik für Innere Medizin</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rupert Bartsch, Prof.</last_name>
      <email>rupert.bartsch@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Grenier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <zip>333000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Dohollou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christelle Levy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cêntre Hospitaler de Cholet</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Zannetti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain Ladoire, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence Venat-Bouvet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nelly Firmin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Ferrero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mony Ung, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Pistilli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gábor Rubovszky, MD</last_name>
      <email>garub@oncol.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cro Irccs</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Spazzapan, MD</last_name>
      <email>spazzapan@cro.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Tondini, MD</last_name>
      <email>carlo.tondini@asst-pg23.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PO Antonio Perrino Brindisi</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cinieri Saverio, MD</last_name>
      <email>saverio.cinieri@ieo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto scientifico Romagnolo per lo studio e la cura</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Rocca, MD</last_name>
      <email>andrea.rocca@irst.emr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Munzone, MD</last_name>
      <email>elisabetta.munzone@ieo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Maggiore Della Carita, University of Eastern Piedmont</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Gennari, MD</last_name>
      <email>alessandra.gennari@med.uniupo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonino Musolino, MD</last_name>
      <email>amusolino@ao.pr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituti Clinici Scientifici Maugeri</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Bernardo, MD</last_name>
      <email>antonio.bernardo@icsmaugeri.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Stefano</name>
      <address>
        <city>Prato</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Biganzoli, MD</last_name>
      <email>laura.biganzoli@uslcentro.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia, Ospedale Infermi</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Gianni, MD</last_name>
      <email>lorenzo.gianni@auslromagna.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>San Cristóbal de La Laguna</city>
        <state>Tenerife</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josefina C Jurado, MD</last_name>
      <email>jcruzjurado@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José J Ponce Lorenzo, MD</last_name>
      <email>joseponcelorenzo@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d´Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meritxell Bellet Ezquerra, MD</last_name>
      <email>mbellet@vhio.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia L´Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael A Villanueva Vázquez, MD</last_name>
      <email>ravillanueva@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena G Calvo, MD</last_name>
      <email>elena.galvecalvo@osakidetza.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva M Ciruelos Gíl</last_name>
      <email>eva.ciruelos@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HU Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noelia Martínez Jañez, MD</last_name>
      <email>mjnoelia@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria R Entrena, MD</last_name>
      <email>nuriaribelles@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología (IVO)</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin Gavila Gregori, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio A Torres, MD</last_name>
      <email>aantont@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Leo, MD</last_name>
      <email>cornelia.leo@ksb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Basel Bethesda Spital</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Thorn, MD</last_name>
      <email>dr.david.thorn@hin.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Rabaglio, MD</last_name>
      <email>manuela.rabaglio@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre du Sein Fribourg</name>
      <address>
        <city>Fribourg</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurant Rosset, MD</last_name>
      <phone>0041 26 347 43 07</phone>
      <email>Rossetl@hin.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Aebi, Prof.</last_name>
      <email>stefan.aebi@luks.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Muller, MD</last_name>
      <email>andreas.mueller@ksw.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brust-Zentrum AG Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Gueth, Prof.</last_name>
      <email>u.gueth@brust-zentrum.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, Geyer CE Jr, Wickerham DL, Costantino JP, Wolmark N. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009 May 20;27(15):2466-73. doi: 10.1200/JCO.2008.19.8424. Epub 2009 Apr 6.</citation>
    <PMID>19349544</PMID>
  </reference>
  <reference>
    <citation>Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, Robidoux A, Bernhard J, Maibach R, Castiglione-Gertsch M, Coates AS, Piccart MJ, Clemons MJ, Costantino JP, Wolmark N; IBCSG; BIG; NSABP. A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. Clin Breast Cancer. 2008 Jun;8(3):287-92. doi: 10.3816/CBC.2008.n.035.</citation>
    <PMID>18650162</PMID>
  </reference>
  <reference>
    <citation>Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, Jungi WF, Thürlimann B, Cavalli F, Obrecht JP, et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol. 1994 Oct;12(10):2071-7.</citation>
    <PMID>7931476</PMID>
  </reference>
  <reference>
    <citation>Aebi S, Gelber S, Anderson SJ, Láng I, Robidoux A, Martín M, Nortier JW, Paterson AH, Rimawi MF, Cañada JM, Thürlimann B, Murray E, Mamounas EP, Geyer CE Jr, Price KN, Coates AS, Gelber RD, Rastogi P, Wolmark N, Wapnir IL; CALOR investigators. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014 Feb;15(2):156-63. doi: 10.1016/S1470-2045(13)70589-8. Epub 2014 Jan 16.</citation>
    <PMID>24439313</PMID>
  </reference>
  <reference>
    <citation>Wapnir IL, Price KN, Anderson SJ, Robidoux A, Martín M, Nortier JWR, Paterson AHG, Rimawi MF, Láng I, Baena-Cañada JM, Thürlimann B, Mamounas EP, Geyer CE Jr, Gelber S, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S; International Breast Cancer Study Group; NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group; Breast International Group. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol. 2018 Apr 10;36(11):1073-1079. doi: 10.1200/JCO.2017.76.5719. Epub 2018 Feb 14.</citation>
    <PMID>29443653</PMID>
  </reference>
  <reference>
    <citation>Migliaccio I, Di Leo A, Malorni L. Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. Curr Opin Oncol. 2014 Nov;26(6):568-75. doi: 10.1097/CCO.0000000000000129. Review.</citation>
    <PMID>25188473</PMID>
  </reference>
  <reference>
    <citation>Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder R, Lai JP, Norris JD, McDonnell DP, Li S. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. Clin Cancer Res. 2015 Nov 15;21(22):5121-5130. doi: 10.1158/1078-0432.CCR-15-0360. Epub 2015 May 19.</citation>
    <PMID>25991817</PMID>
  </reference>
  <reference>
    <citation>Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16.</citation>
    <PMID>25524798</PMID>
  </reference>
  <reference>
    <citation>Turner NC, Huang Bartlett C, Cristofanilli M. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Oct 22;373(17):1672-3. doi: 10.1056/NEJMc1510345.</citation>
    <PMID>26488700</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 25, 2019</study_first_submitted>
  <study_first_submitted_qc>January 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hormone receptor positive breast cancer</keyword>
  <keyword>HER2 receptor negative</keyword>
  <keyword>CDK4/6 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

